Evolus (EOLS) Jefferies Global Healthcare Conference 2026 summary

Business evolution and strategic direction

• Transitioned from a single-product neurotoxin company to a diversified aesthetics portfolio, including HA injectables and upcoming products like Sculpt and a lip filler, with further pipeline assets in development.

• Expanded geographic footprint with direct presence in the UK, major European markets, Australia, and Canada, with international revenue nearly doubling year-on-year and now representing about 8% of total revenue.

• Focused on building deep partnerships with clinics through high-quality products, robust clinical data, and comprehensive go-to-market support, including co-branded media and a consumer loyalty program.

• Digital platform enables efficient scaling, with 17,000 US customers using the app for ordering and billing, and over 1.5 million consumers in the loyalty program.

• Operating expenses remain flat year-on-year due to digital efficiencies, supporting profitability and margin expansion as revenue grows.

Product innovation and clinical differentiation

• HA injectable line, Evolysse, developed with SYMATESE, leverages cold manufacturing technology to preserve HA structure, resulting in biocompatibility, durability, and superior tissue integration.

• Clinician feedback highlights disproportionate correction, forgiving rheology, and natural tissue integration as key differentiators for Evolysse.

• Sculpt, the flagship midface product, is expected to be approved by year-end and is engineered for natural movement and lift, with strong clinician interest in Europe.

• Portfolio approach is emphasized, with different products tailored to varying patient needs, especially for GLP-1 patients experiencing facial volume loss.

• Future portfolio expansion targets biostimulators, skin quality products, and blue-sky innovations like minimally invasive biomaterials for tissue regeneration.

Market trends and growth drivers

• Younger demographics view aesthetics as beauty treatments, driving category growth and higher engagement.

• GLP-1 weight loss drugs are increasing demand for aesthetic treatments, particularly fillers, as patients seek to address facial volume loss.

• Co-branded media and integrated marketing with clinics enhance brand awareness and drive organic and DTC-driven patient inflow.

• US market penetration remains low compared to Brazil and Korea, indicating significant growth potential.

• Combination of toxins and fillers represents half of the global aesthetic market value, positioning the company in the most durable segment.